Imlunestrant is an investigational oral selective estrogen receptor degrader (SERD) developed for the treatment of estrogen receptor (ER)-positive breast cancer. It is designed to bind to the estrogen receptor and promote its degradation, thereby suppressing estrogen-receptor-mediated signaling.
Imlunestrant is being investigated particularly in ER-positive, HER2-negative breast cancer, including settings involving acquired endocrine resistance.
Imlunestrant is a specialized synthetic pharmaceutical compound requiring controlled manufacturing, purification and analytical characterization. Quality evaluation may include identity, assay, related substances, residual solvents, water content, elemental impurities and solid-state characterization.
CAS Number: 2361179-56-4
Molecular Formula: C35H37F2N5O5S
Molecular Weight: 677.77 g/mol
Drug Class: Selective Estrogen Receptor Degrader
Pharmacological Class: Oral SERD
Therapeutic Area: Oncology / Breast Cancer
Imlunestrant binds to the estrogen receptor (ER) and promotes receptor degradation. This reduces the amount of functional estrogen receptor available for estrogen-dependent signaling.
By suppressing ER signaling, Imlunestrant is designed to inhibit proliferation of estrogen receptor-positive breast cancer cells.
Imlunestrant is being investigated in pharmaceutical research involving:
Unlike traditional selective estrogen receptor modulators, oral SERDs are designed to both bind to the estrogen receptor and promote receptor degradation. Imlunestrant is being studied as an orally administered endocrine therapy with potential applications in patients whose tumors have developed resistance to earlier endocrine treatments.
Imlunestrant is a synthetic, fluorine-containing small molecule containing nitrogen, oxygen and sulfur functionalities. Its physicochemical properties are important for pharmaceutical formulation, analytical testing and solid-state characterization.
Imlunestrant API quality evaluation may include:
Imlunestrant should be stored in a tightly closed container under controlled pharmaceutical conditions and protected from excessive moisture, heat and direct light. Final storage requirements should be established through validated stability studies.
Imlunestrant is relevant to research involving estrogen receptor degradation, endocrine resistance, ER-positive breast cancer and next-generation oral endocrine therapies.
Imlunestrant is an investigational oral selective estrogen receptor degrader (SERD) with CAS Number 2361179-56-4, molecular formula C35H37F2N5O5S, and molecular weight 677.77 g/mol. It is being developed for ER-positive breast cancer and works by binding to and promoting degradation of the estrogen receptor.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 2.0% |